| scholarly article | Q13442814 |
| P2093 | author name string | James E Herndon | |
| Robert A Kratzke | |||
| Ramaswamy Govindan | |||
| Mark R Green | |||
| Hedy L Kindler | |||
| Dorothy Watson | |||
| Gloria A Niehans | |||
| Robin Vollmer | |||
| Cancer and Leukemia Group B (CALGB 30101) | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 2300-2304 | |
| P577 | publication date | 2005-03-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. | |
| P478 | volume | 11 |
| Q35855798 | A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. |
| Q54521295 | A comparison of epidermal growth factor receptor expression in malignant peritoneal and pleural mesothelioma. |
| Q47162061 | A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. |
| Q54110132 | A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy. |
| Q38261500 | Advances in malignant peritoneal mesothelioma |
| Q35832903 | Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach |
| Q38800916 | Advances in treatment of mesothelioma. |
| Q38842125 | Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma |
| Q37328307 | Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. |
| Q37335377 | Biomarkers for malignant pleural mesothelioma: current status |
| Q35141369 | Chemotherapy and targeted therapies for unresectable malignant mesothelioma |
| Q37090808 | Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future |
| Q50050310 | Clinical and biologic prognostic factors in malignant pleural mesothelioma |
| Q34267563 | Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma |
| Q37086026 | Current concepts in malignant pleural mesothelioma. |
| Q64899643 | Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations. |
| Q28395184 | DNA copy number gains in malignant pleural mesothelioma |
| Q38059514 | Dendritic cell-based immunotherapy in mesothelioma |
| Q37400550 | Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity |
| Q26768364 | Diagnosis and management of patients with malignant peritoneal mesothelioma |
| Q37833952 | Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research |
| Q36758593 | Emerging drugs for mesothelioma |
| Q54538613 | Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. |
| Q54601144 | Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. |
| Q55181387 | Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial. |
| Q46548604 | Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma |
| Q33760654 | Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib |
| Q36523502 | Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients |
| Q38959812 | Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q36446915 | Gefitinib: an adverse effects profile |
| Q33862523 | HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts |
| Q88924373 | Heterogeneity in Malignant Pleural Mesothelioma |
| Q49996923 | Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications |
| Q52559185 | In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM). |
| Q53990140 | Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. |
| Q37130217 | Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma |
| Q34293068 | Investigational approaches for mesothelioma |
| Q36490313 | Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells |
| Q28395597 | Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies |
| Q87322726 | Malignant mesothelioma |
| Q47098675 | Malignant mesothelioma: Canadian perspective and research directions |
| Q33871582 | Malignant peritoneal mesothelioma: a review |
| Q83412919 | Malignant pleural mesothelioma |
| Q83466825 | Malignant pleural mesothelioma |
| Q84107270 | Malignant pleural mesothelioma |
| Q34513958 | Malignant pleural mesothelioma: an update on diagnosis and treatment options |
| Q38019747 | Malignant pleural mesothelioma: from the bench to the bedside. |
| Q36728254 | Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. |
| Q37277434 | Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). |
| Q36830116 | Management options for malignant pleural mesothelioma: clinical and cost considerations |
| Q26800042 | Mesothelioma treatment: Are we on target? A review |
| Q35839385 | Mesothelioma: a review |
| Q43797861 | Mesothelioma: closer to the target? |
| Q93381841 | Modeling Epidermal Growth Factor Inhibitor-mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture |
| Q37232301 | Molecular biology of malignant mesothelioma |
| Q38012566 | Molecular pathogenesis of malignant mesothelioma |
| Q28397153 | Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma |
| Q39001426 | Multipoint targeting of the PI3K/mTOR pathway in mesothelioma |
| Q36889671 | Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma |
| Q35042668 | New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials |
| Q26859274 | New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas |
| Q89411795 | Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes |
| Q34364821 | Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma |
| Q46255077 | Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma |
| Q33890499 | Novel systemic therapy against malignant pleural mesothelioma |
| Q35129535 | Novel therapies in phase II and III trials for malignant pleural mesothelioma. |
| Q36710964 | Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies |
| Q39377749 | Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors |
| Q24680847 | Peritoneal mesothelioma: a review |
| Q39463417 | Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin |
| Q36159154 | Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma |
| Q39415827 | Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. |
| Q24170504 | Proteasome inhibitor MG132 induces apoptosis and inhibits invasion of human malignant pleural mesothelioma cells |
| Q37020881 | Protein kinase C beta in malignant pleural mesothelioma |
| Q37873380 | Review on clinical trials of targeted treatments in malignant mesothelioma |
| Q38365768 | Searching for targets for the systemic therapy of mesothelioma. |
| Q42938263 | Surgical treatment of malignant peritoneal mesothelioma: past, present, and future |
| Q49387613 | Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro |
| Q34622818 | Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials |
| Q37992694 | Systemic treatment of malignant pleural mesothelioma |
| Q37260408 | Systemic treatments for mesothelioma: standard and novel |
| Q23910293 | TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages |
| Q39606052 | Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma |
| Q35599789 | The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma |
| Q38148036 | The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms |
| Q39290976 | Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma |
| Q38118385 | Therapies currently in Phase II trials for malignant pleural mesothelioma |
| Q36755500 | Update on the molecular biology of malignant mesothelioma |
| Q38758684 | Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials |
| Q82061962 | [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma] |
Search more.